Switch from Remicade to Inflectra Did Not Affect Efficacy, Per Danish Study
Biosimilar Competition Has Led to Consistent Price Reduction in Europe
European Guide for Prescribers Assures Safety and Effectiveness of Biosimilars
Strong Early Launch for New Eczema Drug Dupilumab, Despite Price
Three Studies at DDW 2017 Suggest Infliximab Biosimilar Getting Closer to Interchangeability
Senate Confirms Scott Gottlieb as FDA Commissioner
Drug Pricing Not Discussed at White House Meeting of Biotech Execs and NIH
WHO to Start Pilot Prequalification of Biosimilars for 2 Cancer Treatments
ICER Issues Draft Evidence Report on Biologics for Osteoporosis
Celltrion Plans Filing for Biosimilars to Rituximab, Trastuzumab
Biosimilars at the Gates: What's Ahead?
JAMA Viewpoint Explores Barriers to Biosimilar Uptake for Chronic Diseases
The Uncertainty of BPCIA Litigation Strategies and the "Patent Dance"
Biosimilar Uptake Implies Patient Access to Affordable Medication
Supreme Court Hears Oral Arguments in Biosimilar Patent Dance
Who Will Influence Biosimilar Uptake: Physician, Pharmacist, Patient, or Payer?
Proposed Xolair Biosimilar Gets FDA Approval for Clinical Trials
Advances in the Development of Ranibizumab and Teriparatide Biosimilars
Fresenius Kabi to Purchase Merck KGaA Biosimilars Arm for €670 Million
EMA Recommends 9 New Medicines, Including Biosimilars
Dr Joseph P Fuhr Sees Need for Education Programs on Biosimilars
Second Biosimilar to Infliximab Approved
CVS Caremark Ties Decline in Its Drug Spending to Generics, Biosimilars
US Supreme Court to Consider Sandoz vs Amgen Biosimilar Patent Dance Case on April 26
Rituximab Biosimilar Estimated to Save €90 Million Annually in the EU
Patients' Reluctance to Accept Biosimilars Suggests Need for Better Communication, Education
Nebraska Legislature Debates Biosimilar Substitution Bill
Patent Infringement Litigation: How Early Can It Begin?
In a Surprise Decision, FDA Further Delays Approval of Lilly's RA Drug
Prescribers in England Turn to Biosimilar Growth Hormones for Ease of Use, Not Cost
